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Abstract  The  molecular  classiﬁcation  of  breast  cancers  deﬁnes  subgroups  of  cancer  with  dif-
ferent prognoses  and  treatments.  Each  molecular  type  representing  the  intrinsic  signature  of
the cancer  corresponds  to  a  histological  proﬁle  incorporating  hormone  receptors,  HER2  status
and the  proliferation  index.  This  article  describes  the  correlations  between  this  molecular  clas-
siﬁcation obtained  in  routine  clinical  practice  using  histological  parameters  and  MRI.  It  shows
that there  is  a  speciﬁc  MRI  proﬁle  for  triple-negative  cancers:  distinct  demarcation,  regular
edges, hyperintensity  on  T2  weighted  signals  and,  particularly,  a  crown  enhancement.  It  is
important  for  the  radiologist  to  understand  this  molecular  classiﬁcation,  ﬁrstly  because  of  the
relatively suggestive  appearance  of  triple-negative  basal-like  cancers  in  the  molecular  classi-
ﬁcation,  secondly,  and  particularly,  as  cancers  in  patients  with  the  BRCA1  mutation  are  often
triple-negative  meaning  that  the  criteria  for  reading  the  MRI  needs  to  be  tailored  to  this  fea-
ture of  the  cancers,  and  ﬁnally  because  the  efﬁcacy  of  MRI  in  assessing  response  to  neoadjuvant
chemotherapy  depends  on  the  molecular  class  of  cancer  treated.
© 2014  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
MRI  plays  an  essential  role  in  the  local  staging  assessment  of  breast  cancer,  enabling  a
better  evaluation  of  tumor  size,  revealing  multifocal  or  multicenter  lesions  or  demon-
strating  a  contralateral  lesion,  which  is  found  on  MRI  in  3  to  4%  of  patients  [1].  In
addition  to  this  impact  on  treatment,  MRI  is  of  prognostic  use:  it  is  helpful  in  predict-
ing  early  effectiveness  of  neoadjuvant  chemotherapy,  which  has  been  shown  in  a  recently
published  multicenter  trial  [2]  and  more  generally  it  independently  predicts  relapse-free
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on  non-subtracted  thin  sections.  The  crown  enhancement  is
also  a  classical  sign  of  a  rapidly  growing  tumor  associated
with  a  high  histological  grade  (Fig.  3).  This  enhancement36  
urvival  in  patients  with  breast  cancer  [3].  Identiﬁcation
f  prognostic  factors  is  an  essential  decision-making  fac-
or  in  the  treatment  of  breast  cancers.  In  addition  to
he  main  morphological  prognostic  factors  such  as  tumor
ize  and  the  presence  of  lymph  nodes,  the  treatment  of
reast  cancers  in  based  on  a  number  of  classical  histological
actors,  which  determine  different  prognoses  and  manage-
ent.  These  ‘‘classical’’  histological  factors  are  histological
rade,  the  Ki67  proliferation  index,  estrogen  (ER)  and  pro-
esterone  (PR)  hormone  receptors  and  HER2  status.
In  addition  to  these  classical  histological  features  the
olecular  abnormalities  of  breast  cancers,  which  can  be
xamined  by  genomic  tests  are  also  included.  Whilst  these
enomic  tests  based  on  analysis  of  the  expression  of  anal-
sis  of  RNA  and  DNA  have  limited  applications  in  routine
linical  practice  at  present  in  France,  speciﬁc  correlations
xist  between  the  histological  proﬁle  (incorporating  hor-
one  receptors,  HER2  status  and  the  proliferation  index)
nd  the  different  molecular  types  of  breast  carcinomas  rep-
esenting  their  intrinsic  signature  and  classiﬁed  as  luminal  A,
uminal  B,  HER2-like,  basal-like  and  more  recently,  apocrine
ype  [4—6].
The  aim  of  this  article  is  to  describe  the  correlations
etween  MRI  and  histology  of  inﬁltrating  carcinomas  accord-
ng  to  the  different  conventional  histological  prognostic
actors  and  then  to  describe  the  correlations  between  MRI
nd  the  different  molecular  types  of  inﬁltrating  carcinoma.
inally,  in  a  third  section  we  will  emphasize  the  practical
mpact  of  the  radiologist’s  involvement  in  this  molecu-
ar  classiﬁcation  through  two  speciﬁc  situations:  diagnosis
n  a  patient  with  a  mutation  and  monitoring  neoadjuvant
hemotherapy.
igure 1. A 61-year-old patient with grade 1 inﬁltrating, ductal carci
mage, architectural distortion in a small spiculated left infero-media
rregular mass enhancement with a partly spiculated irregular outlines.
igure 2. A 55-year-old patient with grade 3 inﬁltrating ductal carcin
mage, small difﬁcult to see supero-external mass; b: axial section, subtr
: enhancement at 3 minutes in thin sections providing a better view of 
mC.  Alili  et  al.
orrelations between MRI and classical
istological prognostic factors
he  factors  studied  are  grade  Ki67  proliferation  index,  hor-
one  receptors  and  HER2  status.
umor grade
his  is  based  on  three  histological,  morphological  features:
umor  architecture  with  cell  differentiation,  the  shape  and
ize  of  the  nucleus  and  the  number  of  cells  in  division  or
xhibiting  mitotic  activity.
Classically,  grade  1 tumors  develop  slowly  with  a  large
tromal  reaction  whereas  grade  3  tumors  are  hypercellu-
ar  with  little  stromal  reaction  and  grade  2  tumors  have  an
ntermediary  appearance,  which  is  more  similar  to  that  of
rade  1  tumors.  All  publications  describe  this  appearance
n  MRI  with  spiculated  outlines  (Fig.  1) in  grade  1  can-
ers  [7].  This  is  not  reported  absolutely  consistently  in  all
eries  [8]  for  several  reasons:  tumor  polymorphism,  the  fact
hat  the  small  number  of  patients  included  in  the  different
eries  do  not  always  allow  a  statistically  signiﬁcant  differ-
nce  to  be  identiﬁed,  and  the  conditions  under  which  MRI  is
erformed,  as  irregular  or  spiculated  outlines  can  be  more
asily  seen  on  high  resolution  matrix  investigations  (Fig.  2)
n  thin  sections.  Finally,  the  conditions  under  which  the  MRI
s  read  and  interpreted  have  a  bearing  as  thicker  sections
nd  blurring  due  to  subtraction  may  mask  thin  spicules  seennoma of the left breast, Ki67 = 10%: a: axial section, T2 weighted
l mass; b: axial section, subtraction at 3 minutes, homogeneous
oma of the right breast, Ki67 = 50%: a: axial section, T2 weighted
action at 3 minutes, small homogeneous round mass enhancement;
the irregular outlines.
ay  be  due  to  extensive  angiogenesis  in  the  periphery  of
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Figure 3. A 58-year-old patient with grade 3 inﬁltrating ductal carcinoma of the left breast, hormone receptors negative and no HER2
over-expression. Triple-negative basal-like cancer: a: axial section, T2 weighted image. Deep retroareolar tumor mass with non-spiculated
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Loutlines on intermediary T2 weighted image with a few ﬂuid mic
contrast uptake with thin annular enhancement.
the  tumor  whereas  the  center  is  necrotic  or  ﬁbrosed.  This
crown  enhancement  classically  associated  with  higher  grade
tumors  [9,10]  is  of  particular  value  in  pointing  towards  a
high-grade  tumor  when  the  tumor  outlines  are  regular.  This
is  illustrated  in  a  Japanese  article  [11]  describing  correla-
tions  between  MRI  and  histology.  It  is  also  not  speciﬁc,  as  the
same  ﬁnding  may  be  seen  in  benign  lesions  such  as  inﬂamma-
tory  cysts,  cytosteatonecrosis  and  abscesses  and  it  is  also  not
speciﬁc  for  high  grade  cancer  as  it  may  be  seen  in  intra-cystic
papillary  cancers.
Analysis  of  the  diffusion  coefﬁcient  (ADC)  on  diffusion
imaging  performs  well  to  reﬂect  tumor  cellularity  although
the  results,  which  have  been  published  are  rather  contra-
dictory.  Whilst  one  study  published  over  10  years  ago  [12]
concluded  that  the  ADC  value  correlated  closely  with  tumor
cellularity,  other  reports  [13]  have  shown  that  ADC  corre-
lated  with  histological  type  and  not  with  tumor  cellularity
and  found  no  correlation  between  tumor  grade  and  the  ADC
value.
The Ki67 antigen
This  is  a  proliferation  marker  as  it  is  present  on  cell  nuclei
during  the  proliferation  phase  and  absent  from  the  nuclei  of
quiescent  cells.  It  is  detected  by  the  Ki67  antibody  and  the
Ki67  labeling  index  is  deﬁned  as  the  percentage  of  nuclei
labeled  by  the  Ki67  antibody.  The  correlations  between
MRI  appearances  and  this  cell  proliferation  marker  are  ‘‘at
least’’  the  same  as  those  which  exist  with  grade:  ‘‘at  least’’
as  the  index  is  undoubtedly  a  better  marker  of  tumor  pro-
liferation  and  therefore  as  speed  of  growth  than  grade.
In  one  study  which  included  107  patients  and  examined
correlations  between  MRI  appearances  and  prognostic  fac-
tors  [8],  whereas  no  correlation  was  found  between  MRI
appearances  and  grade  there  was  a  trend  towards  spicu-
lated  tumor  outlines  in  patients  with  a  Ki67  of  under  15%
and  with  non-spiculated  outlines  in  patients  with  a  Ki67  of
over  15%.  Similarly,  an  enhanced  peripheral  crown  was  seen
more  often  in  patients  with  a  high  Ki67.
Hormone receptors
This  is  an  important  prognostic  index  but  a  factor,  which
impacts  even  more  on  treatment  as  it  dictates  whether  or
not  hormone  therapy  is  indicated.  Chen  et  al.  [14]  compared
MRI  appearances  of  ER+  an  ER−  cancers  and  found  that  the
commonest  appearance  in  both  groups  was  with  a  mass.  No
ER+  carcinomas  showed  ‘‘non-mass’’  enhancement,  which
was  found  in  18%  of  ER−  tumors.  The  MRI  appearances  of
I
a
t
bplets; b: axial section, subtraction at 3 minutes. Heterogeneous
he  ER−  cancers  reﬂected  their  aggressive  nature:  more
requent  kinetics  showing  a  washout  effect,  larger  size  and
ore  frequent  lymphadenopathy.
Similarly,  a  study  [15]  which  examined  correlations
etween  histoprognostic  factors  and  annual  MRI  enhance-
ent  found  that  the  ratio  of  peripheral  to  central
icrovasculature  was  signiﬁcantly  higher  in  grade  3 tumors
nd  in  RH−  tumors,  explaining  the  annual  enhancement.
ER2 status
his  also  has  prognostic  but  particularly  therapeutic  impact
hrough  targeted  treatments.  There  are  few  publications  on
he  MRI  appearances  of  HER2  positive  patients  compared
o  other  breast  cancers  [16,17]  and  even  more  so  because
atients  who  over-express  HER2  are  often  analyzed  in  two
ifferent  groups:  one  group  of  ER−  PR−  HER2+  phenotype
‘‘HER2  enriched’’  or  ‘‘HER2-like’’)  and  another  subgroup  of
uminal  B  patients  who  over-expressed  the  HER2  receptor.
In  addition,  the  results  which  have  been  published  are
ery  inconsistent  as  in  the  two  studies  which  included  most
atients,  both  published  in  2012  [16,17]  patients  who  over-
xpressed  HER2  had  MRI  appearances  similar  to  those  of
atients  with  ‘‘triple-negative’’  cancers  in  one  study  [16]
hereas  the  appearances  of  HER2  patients  were  similar  to
hose  in  luminal  cancers  in  the  other  study  [17].
orrelation between MRI and molecular
ype  of breast cancers
uminal A
his  molecular  type  represents  the  majority  of  invasive
uminal  cancers.  These  are  grade  I invasive  ductal  can-
ers  which  express  estrogen  receptors  and  have  a  Ki67  of
 15%  and  also  the  inﬁltrating  lobular  cancers  (Fig.  4).  In
he  majority  of  cases  this  type  of  cancer  is  seen  as  a  mass
ith  irregular  or  spiculated  outlines  and  irregular  in  shape
Fig.  5),  with  heterogeneous  enhancement,  no  peripheral
rown,  no  peri-tumor  edema  and  no  pronounced  hyperin-
ensity  on  T2  weighted  images.
uminal Bn  clinical  practice  this  molecular  type  can  be  deﬁned  as
 grade  2  or  3  carcinoma,  which  expresses  estrogen  recep-
ors  and  has  a  Ki67  proliferation  index  of  ≥  15%.  It  should
e  noted  that  carcinomas  developing  in  the  context  of  the
238  C.  Alili  et  al.
Figure 4. A 61-year-old patient with grade 2 inﬁltrating lobular carcinoma of the right breast, positive hormone receptors (ER 95%, PR
95%), no HER2 over-expression, Ki67 10%. Luminal A carcinoma: a: axial section, T2 weighted image. Irregular trifeuille mass with irregular
outlines and no T2 weighted hyperintensity; b: axial section, subtraction at 3 minutes. No annular enhancement.
Figure 5. A 60-year-old patient with grade 2 inﬁltrating ductal carcinoma of the right breast, positive hormone receptors (ER 80%, PR
80%) no over-expression of the c-erb2 oncoprotein, Ki67 5%. Luminal A carcinoma: a: axial section, T2 weighted image, irregular shaped
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dass with spiculated outlines; b: axial section, subtraction at 3 m
uclear atypia; d: diffuse intense immunohistochemical expression
RCA  2  mutation  often  belong  to  this  molecular  group  and
hat  patients  who  are  HER2  positive  and  express  estrogen
eceptors  are  also  included  in  this  group.
There  is  no  published  information  distinguishing  the  MRI
ppearances  of  luminal  A  and  luminal  B  tumors.  The  reports
hich  describe  rounder  cancers  with  more  regular  outlines
n  patients  with  a  high  tumor  grade  and  high  proliferation
ndex  also  include  triple-negative  phenotype  patients  in  this
roup.  No  publications  refer  to  the  speciﬁc  case  of  patients
ith  hormone-dependent  breast  cancer  and  a  high  tumor
rade  and  proliferation  index.
ER2 (non-luminal)
linically,  this  proﬁle  represents  the  grade  2  or  3  inﬁltrat-
ng  carcinomas  which  do  not  express  estrogen  receptors  and
hich  exhibit  strong  HER2  over  expression  (3+)  on  immuno-
istochemistry,  or  2+  HER2  gene  ampliﬁcation  by  FISH
ﬂuorescence  in  situ  hybridization)  or  by  CISH  (chromogenic
n  situ  hybridization),  regardless  of  Ki67  index.  The  pub-
ished  reports  [16,17]  do  not  describe  speciﬁc  appearances
or  the  HER2  tumors:  in  one  study  they  resembled  triple-
egative  tumors  and  in  the  other  they  resembled  luminal
umors.  There  is  however  a  trend  towards  greater  ‘‘non-
ass’’  enhancement  with  a  prevalence  of  almost  30%  of
n
o
s
as; c: histology slide: good architectural differentiation and slight
trogen receptors.
ases  in  one  series  [16]  in  which  the  cancers  over-expressed
ER2  (Fig.  6).  This  ﬁnding  is  not  consistent,  however,  [17]
nd  we  have  also  found  very  predominant  mass  appearances
n  this  population.  In  addition,  more  of  these  patients  would
ppear  to  have  peri-lesional  edema  than  those  with  luminal
ancers.
asal-like carcinoma
n  genomic  terms,  the  basal-like  carcinomas  exhibit  numer-
us  genomic  changes  with  loss  of  chromosome  segments  and
 P  53-gene  mutation  is  seen  in  almost  100%  of  cases.
Morphologically,  the  basal-like  carcinomas  are  ductal,
sually  grade  3,  and  poorly  differentiated  with  a  rolled  back
argin  combined  with  areas  of  geographical  necrosis  which
s  frequently  central  and  a  peripheral  lymphocyte  inﬁltrate
Fig.  7).  They  exhibit  pronounced  nuclear  atypia  and  have  a
igh  mitotic  index.
Immunophenotypically  they  are  often  ER,  PR  and  HER2
riple-negative,  although  20%  of  triple-negative  carcinomas
o  not  express  basal  markers  and  conversely,  non-triple-
egative  carcinomas  can  express  basal  markers.  In  addition,
ccasional  forms  of  good  prognosis  carcinoma  share  the
ame  basal-like  phenotype  (the  cystic  adenoid  carcinomas
nd  juvenile  secretory  carcinomas)  (RF).  In  practice,  it  is
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Figure 6. A 43-year-old patient with grade 3 inﬁltrating ductal carcinoma of the right breast, negative hormone receptors, strong
HER2 over-expression (3+). HER2-like proﬁle: a: axial section, T2 weighted image; b: axial section, subtraction at 3 minutes. Diffuse
non-mass enhancement in the right breast; c: poorly differentiated carcinoma made up of large cells with nuclear pleomorphism; d:
immunohistochemical HER2 over-expression with intense complete membrane labeling of tumor cells (3+).
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tFigure 7. Histological appearances of a triple-negative, basal-like
differentiated ductal carcinoma; c: good demarcation with ‘‘rolled
important  to  recognize  the  grade  3  triple-negative  basal-like
tumors,  as  these  are  chemosensitive  (apart  from  anthra-
cycline  resistance)  possibly  due  to  their  high  proliferation
index  and/or  high  prevalence  of  P  53  gene  mutation.
Carcinomas  which  occur  in  a  context  of  the  BRCA1  muta-
tion  often  belong  to  this  molecular  group.
The  MRI  appearance  of  triple-negative  carcinomas  is  rela-
tively  speciﬁc,  with  a  number  of  particular  features  [16—19].
Almost  all  have  a  mass  appearance,  and  unlike  other  cancers
the  mass  is  rarely  irregular  in  shape  and  its  outlines  are  more
often  smooth  than  spiculated.  An  enhanced  crown  is  found
in  50%  of  cases  as  is  hyperintensity  on  T2  weighted  imaging
e
o
c
Figure 8. A 52-year-old patient with grade 3 inﬁltrating ductal carcin
expression of the c-erb2 oncoprotein. Triple-negative basal-like cancer: a
junction with regular outlines and pronounced T2 weighted hyperinten
line’’ annular enhancement.inoma: a: inﬂammatory peripheral lymphocyte inﬁltrate; b: poorly
’’ margins.
Fig.  8),  possibly  due  to  tumor  necrosis  (Fig.  9),  which  in
tself  is  a  poor  prognostic  factor  [20].
On  diffusion  weighted  images,  Youk  et  al.  [17]  have  shown
hat  ADC  is  of  greater  value  and  is  independently  associated
ith  the  triple-negative  type,  although  there  is  an  over-
ap  between  the  values  in  the  different  groups  of  cancer,
hich  makes  this  ﬁnding  of  limited  use  in  clinical  prac-
ice.The  contradictory  increase  in  ADC  value  compared  to  the
xpected  hypercellularity  in  these  tumors  is  due  to  necrosis
f  triple-negative  tumors  resulting  in  a  fall  in  their  tumor
ellularity  and  increased  diffusion.
oma of the left breast, negative hormone receptors and no over-
: axial section, T2 weighted image: tumor mass at the left superior
sity; b: axial section, subtraction at 3 minutes. Peripheral ‘‘front
240  C.  Alili  et  al.
Figure 9. A 45-year-old patient with grade 3 inﬁltrating ductal carcinoma of the left breast, negative hormone receptors and no over-
expression of the HER2 oncoprotein. Triple-negative basal-like cancer: a: axial section, T2 weighted image: bulky 75 mm heterogeneous
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tumor mass with extensive necrosis, hyper intense on a T2 weigh
ection, subtraction at 3 minutes. Annular contrast uptake associat
pocrine cancer
ne  group  of  ER−  PR−  carcinomas  has  been  identiﬁed  which
s  different  from  the  basal-like  tumors  and  has  an  apoc-
ine  signature,  with  activation  of  the  androgen  receptor
ignaling  pathway  which  may  open  the  way  to  future  anti-
ndrogen  hormone  treatments.  HER2  ampliﬁcations  are  a
ommon  but  not  constant  ﬁnding.  The  apocrine  tumors  are
ggressive  and  often  bulky  with  a  high  histological  grade,
mboli  are  found  in  50%  of  cases  and  invaded  axillary  lymph
odes  are  also  seen  in  50%  of  cases.  Relapse-free  survival
nd  overall  survival  is  poorer  than  for  the  other  types  of
ancer.  This  proﬁle  of  cancer  does  not  appear  to  have  any
peciﬁc  radiological  features  apart  from  the  fact  that  they
re  diagnosed  at  a  locally  advanced  stage.  To  our  knowl-
dge  there  are  no  articles  describing  the  MRI  appearances
f  these  tumors.
hat is the clinical impact?
hilst  identiﬁcation  of  the  molecular  subtypes  of  breast
ancer  impacts  on  management,  the  utility  of  predicting
olecular  subtype  from  MRI  appearances  is  not  as  well
ccepted,  as  all  of  these  tumors  will  in  any  event  be  biop-
ied.  The  tumor’s  molecular  subtype  is  then  deﬁned  in
linical  practice  from  the  biopsy  results  as  luminal  A,  lumi-
al  B,  HER2-like,  basal-like,  or  apocrine.  A  triple-negative
ancer  suspected  before  biopsy  from  MRI  appearances  (as
ith  mammography  or  ultrasound  appearances)  could  help
o  expedite  and  accelerate  management.  In  practice,  apart
rom  the  need  for  radiologists  to  understand  the  language
sed  by  other  disciplines,  understanding  the  correlations
etween  MRI  appearances  and  the  molecular  type  of  the
ancer  has  clinical  impact  in  two  situations:  diagnosis  in
atients  with  a  BRCA  1  mutation  and  the  MRI  follow-up
f  patients  receiving  neoadjuvant  chemotherapy,  success
f  which  depends  on  the  molecular  type  of  the  can-
er.
RI screening in patients with a BRCA 1
utation
he  majority  of  carcinomas  (85%),  which  occur  in  a
ontext  of  the  inherited  BRCA  1  mutation  share  the
t
a
e
fmage. Bulky retropectoral metastatic lymphadenopathy; b: axial
th a large central necrotic component.
mmunophenotypic,  morphological  and  molecular  features
f  the  basal-like  tumors  [21],  with  a  very  high  prevalence  of
riple-negative  cancers.
Conversely,  carcinomas  which  occur  in  the  context  of
he  inherited  BRCA  2  mutations  usually  belong  to  the  lumi-
al  B  type,  explaining  why  the  BRCA  2  cancers  often  have
he  same  MRI  appearances  as  sporadic  cancers  although  the
RCA  1  cancers  have  speciﬁc  MRI  appearances  and  are  typ-
cally  rounded  or  ovular  in  shape,  with  regular  outlines,
n  enhanced  peripheral  crown  and  hyperintensity  on  T2
eighted  images.  This  classical  appearance,  however,  is  not
 constant  ﬁnding  and  the  BRCA  1  tumors  can  also  appear
dentical  to  sporadic  cancers  [19,22].  The  two  most  char-
cteristic,  although  not  invariable,  appearances  associated
ith  the  BRCA  1  mutation  are  peripheral  crown  enhance-
ent  and  prepectoral  tumor  location  [23].
RI monitoring on neoadjuvant chemotherapy
he  performance  of  MRI  in  assessment  of  response  to  neoad-
uvant  chemotherapy  depends  on  the  molecular  class  of
ancer.  This  is  an  important  factor,  which  radiologists  need
o  understand  as  it  may  impact  on  surgical  management
fter  neoadjuvant  chemotherapy.
Two  large  studies,  one  of  which  included  203  patients
reated  with  neoadjuvant  chemotherapy  [24]  and  the
ther,  which  included  746  patients  in  a  retrospective,
ulticenter  study  [25]  reported  entirely  consistent  MRI
erformance  results,  both  for  the  diagnosis  of  complete
esponse  and  for  the  correlation  between  residual  tumor
ize  on  MRI  and  pathological  anatomy:  MRI  provides  a
ore  reliable  assessment  of  tumor  response  after  neoadju-
ant  chemotherapy  in  HER2-like  cancers  or  triple-negative
ancers  than  in  cancers  which  over-express  hormone  recep-
ors.
Whilst  diffusion  weighted  MRI  appears  to  provide  limited
nformation  compared  to  morphological  MRI  to  assess  late
esponse  [26], it  may  be  useful  in  pretreatment  prediction  of
umor  response  to  neoadjuvant  chemotherapy  as  compared
o  the  series  described  above,  a  small  series  has  shown  that
 high  ADC,  reﬂecting  high  diffusion  and  suggesting  large
xtracellular  volume,  is  a  signiﬁcant  predictive  indicator  for
ailure  of  the  tumor  to  respond  [27].
lecu
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[Correlation  between  MR  imaging:  Prognostic  factors  and  mo
Conclusion
In  conclusion,  the  correlations  between  MRI  appearances
and  the  molecular  classiﬁcation  of  breast  cancers  need  to
be  understood  as  some  appearances  are  relatively  sugges-
tive  of  triple-negative  breast  cancer.  These  should  be  looked
for  particularly  in  patients  with  a  BRCA  1  mutation  and  also
because  the  performance  of  MRI  is  assessing  the  efﬁcacy  of
neoadjuvant  chemotherapy  depends  on  the  molecular  pro-
ﬁle  of  the  cancer.
TAKE  HOME  MESSAGES
• Immunohistochemical  results  provide  a  reliable
assessment  of  the  molecular  characteristics  of  the
cancer:  luminal  A,  luminal  B,  HER2-like  and  basal-
like.  The  appearances  of  luminal  A,  luminal  B,
and  to  a  lesser  extent,  HER2  tumors  cannot  be
distinguished.
• There  are  suggestive  signs  of  triple-negative  basal-
like  cancer:  round  shape,  distinct  outlines,  T2
weighted  hyperintensity  and  peripheral  crown
enhancement.
• MRI  performs  better  in  the  assessment  of  response  to
neoadjuvant  chemotherapy  in  HER2,  basal-like  and
HER2-like  cancers  than  in  luminal  cancers.
Disclosure of interest
The  authors  have  not  supplied  their  declaration  of  conﬂict
of  interest.
References
[1] Kuhl CK. Current status of breast MRI imaging. Part 2. Clinical
applications. Radiology 2007;244:672—91.
[2] Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen
MA, Morris EA, et al. Locally advanced breast cancer: MRI
imaging for prediction of response to neoadjuvant chemother-
apy — results from ACRIN 6657/I-SPY TRIAL. Radiology
2012;263:663—72.
[3] Yi A, Cho N, Im SA, Chang JM, Kim SJ, Moon HG, et al. Survival
outcomes of breast cancer patients who receive neoadjuvant
chemotherapy: association with dynamic contrast-enhanced
MRI imaging with computer-aided evaluation. Radiology
2013;268:662—72.
[4] Vincent-Salomon A, Sigal-Zafrani B.Vers une nouvelle classiﬁ-
cation des cancers du sein: apport de la biologie moléculaire.
2009. p. 41—5.
[5] De Abreu FB, Wells WA, Tsongalis GJ. The emerging role of the
molecular diagnostics laboratory in breast cancer personalized
medicine. Am J Pathol 2013;183:1075—83.
[6] Boisserie-Lacroix M, Hurtevent-Labrot G, Ferron S, Lippa N,
Bonnefoi H, Mac Grogan G. Correlation between imaging and
molecular classiﬁcation of breast cancers. Diagn Interv Imaging
2013;94:1069—80.
[7] Chang YW, Kwon KH, Choi DL, et al. Magnetic resonance imag-
ing of breast cancer and correlation with prognostic factors.
Acta Radiol 2009;50:990—8.
[lar  classiﬁcation  241
[8] Jeh SK, Kim SH, Kim HS, Kang BJ, Jeong SH, Yim HW, et al.
Correlation of the apparent diffusion coefﬁcient value and
dynamic magnetic resonance imaging ﬁndings with prognostic
factors in invasive ductal carcinoma. J Magn Reson Imaging
2011;33:102—9.
[9] Szabó BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Boné B. Inva-
sive breast cancer: correlation of dynamic MRI features with
prognostic factors. Eur Radiol 2003;13:2425—35.
10] Lee SH, Cho N, Kim SJ, et al. Correlation between high reso-
lution dynamic MRI features and prognostic factors in breast
cancer. Korean J Radiol 2008;9:10—8.
11] Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer:
correlation between MRI imaging and pathologic ﬁndings. Radi-
ology 2009;250:638—47.
12] Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, et al. Dif-
ferentiation of clinically benign and malignant breast lesions
using diffusion-weighted imaging. J Magn Reson Imaging
2002;16:172—8.
13] Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S,
Mochizuki T, et al. Relation between cancer cellularity and
apparent diffusion coefﬁcient values using diffusion-weighted
magnetic resonance imaging in breast cancer. Radiat Med
2008;26:222—6.
14] Chen JH, Baik HM, Nalcioglu O, Su MY. Estrogen receptor and
breast MRImaging features: a correlation study. J Magn Reson
Imaging 2008;27:825—33.
15] Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW, Thelen M,
et al. Dynamic MRI imaging of breast lesions: correlation with
microvessel distribution pattern and histologic characteristics
of prognosis. Radiology 2006;239:351—60.
16] Costantini M, Belli P, Distefano D, Buﬁ E, Matteo MD,
Rinaldi P, et al. Magnetic resonance imaging features
in triple-negative breast cancer: comparison with lumi-
nal and HER2-overexpressing tumors. Clin Breast Cancer
2012;12:331—9.
17] Youk JH, Son EJ, Chung J, Kim JA, Kim EK. Triple-negative
invasive breast cancer on dynamic contrast-enhanced and
diffusion-weighted MRI imaging: comparison with other breast
cancer subtypes. Eur Radiol 2012;22:1724—34.
18] Uematsu T, Kasami M, Nicholson BT. Rim-enhancing breast
masses with smooth or spiculated margins on magnetic reso-
nance imaging: histopathology and clinical signiﬁcance. Jpn J
Radiol 2011;29:609—14.
19] Noh JM, Han BK, Choi DH, Rhee SJ, Cho EY, Huh SJ, et al.
Association between BRCA mutation status, pathological ﬁnd-
ings, and magnetic resonance imaging features in patients
with breast cancer at risk for the mutation. J Breast Cancer
2013;16:308—14.
20] Jinguji M, Kajiya Y, Kamimura K, Nakajo M, Sagara Y, Takahama
T, et al. Rim enhancement of breast cancers on contrast-
enhanced MRI imaging: relationship with prognostic factors.
Breast Cancer 2006;13:64—73.
21] Foulkes WD,  Stefansson IM, Chappuis PO, et al. Germline BRCA1
mutations and a basal epithelial phenotype in breast cancer.
JNCI Cancer Spectr 2003;95:1482—5.
22] Gilbert FJ, Warren RM, Kwan-Lim G, Thompson DJ, Eeles RA,
Evans DG, et al. Cancers in BRCA1 and BRCA2 carriers and in
women at high risk for breast cancer: MRI imaging and mam-
mographic features. Radiology 2009;252:358—68.
23] Schrading S, Kuhl CK. Mammographic, US, and MRI imag-
ing phenotypes of familial breast cancer. Radiology
2008;246:58—70.
24] McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M,
et al. MRI staging after neoadjuvant chemotherapy for breast
cancer: does tumor biology affect accuracy? Ann Surg Oncol
2011;18:3149—54.
25] De Los Santos JF, Cantor A, Amos KD, Forero A, Gol-
shan M, Horton JK, et al. Magnetic resonance imaging as
2[
[
Cremoux P, Varna M, et al. Diffusion-weighted MRI in pre-
treatment prediction of response to neoadjuvant chemother-42  
a predictor of pathologic response in patients treated with
neoadjuvant systemic treatment for operable breast cancer.
Translational Breast Cancer Research Consortium trial 017.
Cancer 2013;119(10):1776—83.
26] Thomassin-Naggara I, De Bazelaire C, Chopier J, Bazot M,
Marsault C. Trop I. Diffusion-weighted MRI imaging of the
breast: advantages and pitfalls. Eur J Radiol 2013;82:435—43.C.  Alili  et  al.
27] Richard R, Thomassin I, Chapellier M, Scemama A, deapy in patients with breast cancer. Eur Radiol 2013;23:
2420—31.
